Oncolytics faces going concern warning with $5.5M cash despite FDA Fast Track win

Filed May 14, 2026 · Period ending March 31, 2026 · ~1 min read

Key Changes

• high

  Company discloses substantial doubt about continuing operations; $5.5M cash insufficient to fund planned activities for 12 months even with ATM equity sales available.

  MD&A: Liquidity verify on EDGAR →
• high

  FDA granted Fast Track Designation for pelareorep in second-line colorectal cancer based on 33% response rate vs 10% standard-of-care and 27-month survival vs 11 months.

  MD&A: Clinical Programs verify on EDGAR →
• high

  Net loss nearly doubled to $9.2M in Q1 2026 from $4.7M prior year; company sold 10M shares at declining prices ($1.06 in Q1, then $0.92 in April-May) raising $10M net.

  MD&A: Financial Results verify on EDGAR →